Advertisement

Topics

PhaseBio Pharmaceuticals, Inc. Company Profile

01:51 EDT 31st May 2016 | BioPortfolio

PhaseBio Pharmaceuticals, Inc. (PhaseBio), located in Research Triangle Park, NC, is a development stage, privately held protein engineering company focused on developing the next generation of biopharmaceuticals. The company's versatile technology is based on biopolymers of elastin-like repeating subunits to which drugs can be attached or peptides and proteins genetically fused, enhancing the pharmacology and delivery of therapeutics.


News Articles [805 Associated News Articles listed on BioPortfolio]

FDA grants orphan status to cardiomyopathy treatment from PhaseBio

PhaseBio Pharmaceuticals' injectable Vasomera has been awarded orphan drug status by the FDA as a treatment for dystrophinopa -More- 

Duke U. obtains rights to PhaseBio's drug-delivery technology

The exclusive rights to PhaseBio Pharmaceuticals' elastin-like polypetide technology platform, a drug-delivery technology, ha -More- 

PhaseBio, Duke University deal

PhaseBio Announces Leadership Team Appointments

John S. Lee, M.D., Ph.D., named Chief Medical OfficerJohn P. Sharp, CPA, named Chief Financial Officer MALVERN, Pa., April 07, 2016 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-s...

PhaseBio to Present at Needham & Company’s 15th Annual Healthcare Conference

MALVERN, Pa., April 04, 2016 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developin...

PhaseBio to Present at 23rd Annual Future Leaders in the Biotech Industry Conference

MALVERN, Pa., March 04, 2016 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developin...

PhaseBio Receives FDA Orphan Drug Designation for Vasomera (PB1046) for the Treatment of Cardiomyopathy Associated With Dystrophinopathies

MALVERN, Pa., Dec. 1, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing trea...

PhaseBio Licenses Elastin-Like Polypeptide Biopolymer Technology to Duke University for Development of Small-Molecule Oncologic Drugs

Duke gains rights to ELP-small molecule conjugates in oncology  PhaseBio retains rights to ELP technology in all other applications MALVERN, Pa., March 24, 2016 (GLOBE NEWSWIRE) -- PhaseBio Pha...

Drugs and Medications [0 Results]

None

PubMed Articles [131 Associated PubMed Articles listed on BioPortfolio]

Removal of pharmaceuticals from secondary effluents by an electro-peroxone process.

This study compared the removal of pharmaceuticals from secondary effluents of wastewater treatment plants (WWTPs) by conventional ozonation and the electro-peroxone (E-peroxone) process, which involv...

Ranking Prescribed Pharmaceuticals in Terms of Environmental Risk: Inclusion of Hospital Data and the Importance of Regular Review.

A newly available dataset on pharmaceuticals used in Scottish hospitals enabled an Environmental Risk Assessment that includes hospital consumption of pharmaceuticals, as previous UK rankings have bee...

Uptake, depuration, and bioconcentration of two pharmaceuticals, roxithromycin and propranolol, in Daphnia magna.

The objective of the present study was to investigate the uptake, depuration, and bioconcentration of two pharmaceuticals, roxithromycin (ROX) and propranolol (PRP), in Daphnia magna via aqueous expos...

Acute toxicities of pharmaceuticals toward green algae. mode of action, biopharmaceutical drug disposition classification system and quantile regression models.

The acute toxicities of 36 pharmaceuticals towards green algae were estimated from a set of quantile regression models representing the first global quantitative structure-activity relationships. The ...

Assessing environmental risk of pharmaceuticals in Portugal: An approach for the selection of the Portuguese monitoring stations in line with Directive 2013/39/EU.

In line with the Directive 2013/39/EU the most representative surface waters, regarding pharmaceuticals contamination, were selected based on a Portuguese nationwide monitoring exercise. To meet this ...

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc. (PhaseBio), located in Research Triangle Park, NC, is a development stage, privately held protein engineering company focused on developing the next...

More Information about "PhaseBio Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of PhaseBio Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of PhaseBio Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about PhaseBio Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PhaseBio Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant PhaseBio Pharmaceuticals, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record